Our findings are consistent with previous studies showing blocking TNFR2 with antagonistic antibodies could similarly inhibit Tregs (25, 43) and the surrogate antibody could exert in-vivo anti-tumor activity in murine cancer models (44). The gene discussed is TNFRSF1B; the disease is cancer.